Management of kidney cancer in Asia: resource-stratified guidelines from the Asian Oncology Summit 2012
- PMID: 23117003
- DOI: 10.1016/S1470-2045(12)70433-3
Management of kidney cancer in Asia: resource-stratified guidelines from the Asian Oncology Summit 2012
Abstract
Treatment of renal-cell carcinoma has progressed over the past decade, in terms of surgical and systemic therapy. Current treatment guidelines are based on clinical evidence, but do not take into account resource limitations among different countries. These limitations, which include financial and logistical challenges and lack of skilled health-care professionals, have the greatest effect in low-income countries. This consolidated statement gives treatment recommendations for renal-cell carcinoma that are based on clinical evidence and stratified according to extent of resource availability. The statement was formulated by a panel of urologists, medical oncologists, and clinical oncologists from Asian countries, at a consensus session on kidney cancer that was held as part of the 2012 Asian Oncology Summit in Singapore. Resource levels are defined according to a four-tier system (basic, limited, enhanced, and maximum), and treatment recommendations are specified based on availability of financial, skill, and logistical resources.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Similar articles
-
Management of prostate cancer in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013.Lancet Oncol. 2013 Nov;14(12):e524-34. doi: 10.1016/S1470-2045(13)70451-0. Lancet Oncol. 2013. PMID: 24176571 Review.
-
First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009.Lancet Oncol. 2009 Nov;10(11):1102-10. doi: 10.1016/S1470-2045(09)70238-4. Lancet Oncol. 2009. PMID: 19880064 Review.
-
Management of endometrial cancer in Asia: consensus statement from the Asian Oncology Summit 2009.Lancet Oncol. 2009 Nov;10(11):1119-27. doi: 10.1016/S1470-2045(09)70290-6. Lancet Oncol. 2009. PMID: 19880066 Review.
-
Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009.Lancet Oncol. 2009 Nov;10(11):1093-101. doi: 10.1016/S1470-2045(09)70265-7. Lancet Oncol. 2009. PMID: 19880063 Review.
-
Management of adult and paediatric acute lymphoblastic leukaemia in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013.Lancet Oncol. 2013 Nov;14(12):e508-23. doi: 10.1016/S1470-2045(13)70452-2. Lancet Oncol. 2013. PMID: 24176570 Free PMC article. Review.
Cited by
-
P2X7 receptor predicts postoperative cancer-specific survival of patients with clear-cell renal cell carcinoma.Cancer Sci. 2015 Sep;106(9):1224-31. doi: 10.1111/cas.12736. Epub 2015 Jul 29. Cancer Sci. 2015. PMID: 26179886 Free PMC article.
-
MCPIP1 contributes to clear cell renal cell carcinomas development.Angiogenesis. 2017 Aug;20(3):325-340. doi: 10.1007/s10456-017-9540-2. Epub 2017 Feb 14. Angiogenesis. 2017. PMID: 28197812 Free PMC article.
-
Expression of IL-4 and IL-13 predicts recurrence and survival in localized clear-cell renal cell carcinoma.Int J Clin Exp Pathol. 2015 Feb 1;8(2):1594-603. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 25973044 Free PMC article.
-
Quality assessment of kidney cancer clinical practice guidelines using AGREE II instrument: A critical review.Medicine (Baltimore). 2019 Oct;98(40):e17132. doi: 10.1097/MD.0000000000017132. Medicine (Baltimore). 2019. PMID: 31577704 Free PMC article.
-
Transforming growth factor-β1 enhances proliferative and metastatic potential by up-regulating lymphoid enhancer-binding factor 1/integrin αMβ2 in human renal cell carcinoma.Mol Cell Biochem. 2020 Feb;465(1-2):165-174. doi: 10.1007/s11010-019-03676-8. Epub 2019 Dec 17. Mol Cell Biochem. 2020. PMID: 31848806
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous